To evaluate the safety of intravitreal (IVT) Fovista® administered in combination with anti-VEGF therapy.

NCT02387957

Conditions

1. Age-Related Macular Degeneration

Interventions

1. Drug: Fovista®
2. Drug: bevacizumab
3. Drug: ranibizumab
4. Drug: aflibercept

MeSH:Macular Degeneration

Subjects will be treated with "combination therapy" of IVT Fovista® and IVT anti-VEGF therapy every month for the first 5 months (Day 1, Months 1,2,3,4), followed by Q12W (every 12 weeks) administration (Months 7,10, 13,16, 19 and 22), for a total of 24 months. --- Q12W ---

This randomized pilot clinical trial studies the side effects of tremelimumab with or without tissue cryoablation in treating patients with kidney cancer that has spread to other places in the body. Tremelimumab binds to a protein called cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which is found on the surface of T cells (a type of white blood cell). Tremelimumab may block CTLA-4 and help the immune system kill cancer cells. Cryoablation is a procedure that uses a hollow, thin tube called a cryoprobe to freeze and destroy cancer tissue. It is not yet known whether tremelimumab with or without cryoablation is effective in treating patients with kidney cancer.

NCT02626130

Conditions

1. Clear Cell Renal Cell Carcinoma
2. Metastatic Renal Cell Cancer
3. Stage IV Renal Cell Cancer AJCC v7

Interventions

1. Procedure: Cryosurgery
2. Other: Laboratory Biomarker Analysis
3. Procedure: Therapeutic Conventional Surgery
4. Biological: Tremelimumab

MeSH:Carcinoma Carcinoma, Renal Cell

HPO:Carcinoma Clear cell renal cell carcinoma Papillary renal cell carcinoma Renal cell carcinoma

After surgery or biopsy, patients receive tremelimumab IV every 4 weeks (Q4W) for 3 doses, and then every 12 weeks (Q12W) in the absence of disease progression or unacceptable toxicity. --- Q12W ---

After surgery or biopsy, patients receive tremelimumab IV Q4W for 3 doses, and then Q12W in the absence of disease progression or unacceptable toxicity. --- Q12W ---

This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).

NCT03622580

Conditions

1. Diabetic Macular Edema

Interventions

1. Drug: Aflibercept
2. Drug: Faricimab
3. Drug: Sham Procedure

MeSH:Macular Edema Edema

HPO:Anasarca Cystoid macular edema Edema Macular edema

Percentage of Participants in the Faricimab As Specified in Protocol Arm on a Q4W, Q8W, Q12W, or Q16W Treatment Interval at 1 Year. --- Q12W ---

Percentage of Participants in the Faricimab As Specified in Protocol Arm on a Q4W, Q8W, Q12W, or Q16W Treatment Interval at 2 Years. --- Q12W ---

This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME). The global enrollment phase has closed, but participants are still being recruited only at sites in China.

NCT03622593

Conditions

1. Diabetic Macular Edema

Interventions

1. Drug: Aflibercept
2. Drug: Faricimab
3. Drug: Sham Procedure

MeSH:Macular Edema Edema

HPO:Anasarca Cystoid macular edema Edema Macular edema

Percentage of Participants in the Faricimab As Specified in Protocol Arm on a Q4W, Q8W, Q12W, or Q16W Treatment Interval at 1 Year. --- Q12W ---

Percentage of Participants in the Faricimab As Specified in Protocol Arm on a Q4W, Q8W, Q12W, or Q16W Treatment Interval at 2 Years. --- Q12W ---

This study will evaluate the efficacy, safety, durability, and pharmacokinetics of KSI-301 administered at 12, 16 and 20 weeks intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with treatment-naïve neovascular (wet) age-related macular degeneration (nAMD).

NCT04049266

Conditions

1. Wet Macular Degeneration

Interventions

1. Drug: KSI-301
2. Drug: Aflibercept
3. Other: Sham Procedure

MeSH:Macular Degeneration Wet Macular Degeneration

Mean change in Best Corrected Visual Acuity (BCVA) from Day 1.. BCVA is measured using ETDRS visual acuity charts.. Proportion of subjects on a Q12W, Q16W or Q20W dosing regimen of KSI-301.. null. --- Q12W ---